Literature DB >> 20071053

The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease.

Luke Richards1, Daniela M Ferreira, Eliane N Miyaji, Peter W Andrew, Aras Kadioglu.   

Abstract

The human nasopharynx is an important ecological niche for Streptococcus pneumoniae, and asymptomatic nasopharyngeal carriage is a common precursor to invasive disease. However, knowledge of the immunological events, which occur during carriage, both on a cellular and humoral level, remains limited. Here, we present a long-term stable model of asymptomatic nasopharyngeal carriage using outbred naïve mice, in which we have investigated the effect of previous nasopharyngeal exposure to pneumococci, in the prevention of subsequent carriage and invasive disease. Carriage of D39 wildtype pneumococci restricted to the nasopharynx could be detected for at least 28 days post-infection, whereas nasopharyngeal carriage of a pneumolysin negative isogenic mutant (PLN-A) was cleared in 7-14 days. Both carriage events induced total and capsule specific IgA mucosal antibodies and increased levels of systemic antibodies (IgG against pneumococcal surface protein A (PspA) and IgM capsular polysaccharide), which increased over time and correlated to reduced nasopharyngeal pneumococcal numbers. Prior nasopharyngeal colonisation with PLN-A significantly reduced the duration of subsequent D39 wildtype carriage, and significantly increased survival following invasive pneumococcal challenge. In this case systemic anti-PspA and anti-capsular antibody IgM concentrations showed a strong correlation with reduced bacterial numbers in the lungs and nasopharynx, respectively and also with increased levels of IL17A and CD4+ T cells in lungs of pre-colonised mice. Prior nasopharyngeal colonisation with PLN-A also resulted in significant cross-serotype protection with mice protected from invasive disease with serotype 3 strain (A66) after pre-colonisation with a serotype 2 strain (D39). Our results suggest that both mucosal and systemic antibody as well as cellular host factors have a role in long-term protection against both colonisation and invasive pneumococcal challenge. 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20071053     DOI: 10.1016/j.imbio.2009.12.004

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  49 in total

1.  Infection with conditionally virulent Streptococcus pneumoniae Δpab strains induces antibody to conserved protein antigens but does not protect against systemic infection with heterologous strains.

Authors:  Suneeta Chimalapati; Jonathan Cohen; Emilie Camberlein; Claire Durmort; Helen Baxendale; Corné de Vogel; Alex van Belkum; Jeremy S Brown
Journal:  Infect Immun       Date:  2011-09-26       Impact factor: 3.441

2.  Mucosal immunization with the live attenuated vaccine SPY1 induces humoral and Th2-Th17-regulatory T cell cellular immunity and protects against pneumococcal infection.

Authors:  Xiuyu Xu; Hong Wang; Yusi Liu; Yiping Wang; Lingbing Zeng; Kaifeng Wu; Jianmin Wang; Feng Ma; Wenchun Xu; Yibing Yin; Xuemei Zhang
Journal:  Infect Immun       Date:  2014-10-13       Impact factor: 3.441

3.  Protection against Streptococcus pneumoniae Invasive Pathogenesis by a Protein-Based Vaccine Is Achieved by Suppression of Nasopharyngeal Bacterial Density during Influenza A Virus Coinfection.

Authors:  M Nadeem Khan; Qingfu Xu; Michael E Pichichero
Journal:  Infect Immun       Date:  2017-01-26       Impact factor: 3.441

4.  Double-Edged Role of Interleukin 17A in Streptococcus pneumoniae Pathogenesis During Influenza Virus Coinfection.

Authors:  Ganesh Ambigapathy; Taylor Schmit; Ram Kumar Mathur; Suba Nookala; Saad Bahri; Liise-Anne Pirofski; M Nadeem Khan
Journal:  J Infect Dis       Date:  2019-07-31       Impact factor: 5.226

5.  Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans.

Authors:  M Nadeem Khan; Michael E Pichichero
Journal:  Vaccine       Date:  2012-02-17       Impact factor: 3.641

6.  Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.

Authors:  Paul V Licciardi; Fiona M Russell; Anne Balloch; Robert L Burton; Moon H Nahm; Gwendolyn Gilbert; Mimi L K Tang; Edward K Mulholland
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

Review 7.  Streptococcus pneumoniae: transmission, colonization and invasion.

Authors:  Jeffrey N Weiser; Daniela M Ferreira; James C Paton
Journal:  Nat Rev Microbiol       Date:  2018-06       Impact factor: 60.633

Review 8.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

9.  Inflammation-associated cytokine analysis identifies presence of respiratory bacterial pathogens in the nasopharynx.

Authors:  Michael E Pichichero; Anthony Almudevar
Journal:  Pathog Dis       Date:  2016-08-04       Impact factor: 3.166

10.  Density and duration of pneumococcal carriage is maintained by transforming growth factor β1 and T regulatory cells.

Authors:  Daniel R Neill; William R Coward; Jenna F Gritzfeld; Luke Richards; Francesc J Garcia-Garcia; Javier Dotor; Stephen B Gordon; Aras Kadioglu
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.